Antisense Therapeutics Limited (ATHJF)
Stock analysis · OTC · Healthcare · Drug Manufacturers - Specialty & Generic
Antisense Therapeutics Limited (ATHJF) is a publicly traded company in the Healthcare sector. Latest price: $0.01. Market cap $19.64M. Trailing PE -1.26. Sign in to Stocks360 for full DCF valuation, fundamentals, technicals, and AI-driven analysis.
Get full analysis → Short-Term Analysis →Earnings
Proprietary Signals
About Antisense Therapeutics Limited
Antisense Therapeutics Limited (ATHJF) is an Australian biotechnology company dedicated to the research and development of innovative antisense pharmaceuticals. Its therapeutic pipeline includes two primary drug candidates. ATL1102, an antisense inhibitor targeting CD49d, is currently in Phase II clinical trials for a variety of inflammatory conditions, such as multiple sclerosis, Duchenne Muscular Dystrophy, and asthma. The company's second candidate, ATL1103, is an advanced second-generation antisense medication. This drug works by blocking growth hormone receptor expression, which subsequently lowers levels of insulin-like growth factor-I (IGF-I) in the bloodstream, and has successfully completed Phase II clinical trials for diseases linked to excessive growth hormone activity. Antisense Therapeutics Limited was established in 2000 and operates from its base in Toorak, Australia.
Valuation
| P/E (TTM) | -1.26× |
|---|---|
| P/S (TTM) | 9.40× |
| P/B | 1.60× |
| P/FCF (TTM) | -2.76× |
| EV / EBITDA | -1.35× |
| EV / Sales | 5.42× |
| Earnings Yield | -79.33% |
| Free Cash Flow Yield | -36.27% |
Fundamentals
| Enterprise Value | $16.07M |
|---|---|
| Revenue (TTM) | $2.97M |
| Net Income (TTM) | -$22.13M |
| Free Cash Flow (TTM) | -$10.12M |
| Net Debt | -$11.83M |
| Working Capital | $9.32M |
| Gross Margin | 97.91% |
| Operating Margin | -398.65% |
| Net Margin | -401.57% |
| Return on Equity | -123.27% |
| Return on Invested Capital | -125.64% |
Peers
Recent News
- No recent news available.
Related
Browse more tickers: sitemap